Chronic Myeloid Leukemia: Diagnosis and Treatment

Quintas-Cardama, Alfonso; Cortes, Jorge E.
July 2006
Mayo Clinic Proceedings;Jul2006, Vol. 81 Issue 7, p973
Academic Journal
Chronic myeloid leukemia (CML) has become a model in research and management among malignant disorders. Since the discovery of the presence of a unique and constant chromosomal abnormality slightly more than 40 years ago, substantial progress has been made in the understanding of the biology of the disease. This progress has translated into significant improvement in the long-term prognosis of patients with this disease. This change came first with the use of stem cell transplantation and interferon alfa, but recently it has opened the era of molecularly targeted therapies. Imatinib, a potent and selective tyrosine kinase inhibitor, may be the best example of our attempts to identify molecular abnormalities and develop drugs directed specifically at them. Furthermore, the understanding of at least some of the mechanisms of resistance to imatinib has led to rapid development of new agents that may overcome this resistance. The outlook today for patients with CML is much brighter than just a few years ago. It is our hope that this fascinating journey in CML can be replicated in other malignancies. In this article, we review our current understanding of this disease.


Related Articles

  • Imatinib.  // Reactions Weekly;8/11/2007, Issue 1164, p15 

    The article describes the case of a 60-year-old woman who developed Stevens-Johnson syndrome (SJS) during treatment with imatinib for Philadelphia, Pennsylvania-positive chronic myeloid leukaemia (CML). The patient started treatment after being diagnosed with CML, and twelve days later, she...

  • Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Villuendas, R.; Steegmann, J. L.; Pollán, M.; Tracey, L.; Granda, A.; Fernández-Ruiz, E.; Casado, L. F.; Martínez, J.; Martínez, P.; Lombardía, L.; Villalón, L.; Odriozola, J.; Piris, M. A. // Leukemia (08876924);Jun2006, Vol. 20 Issue 6, p1047 

    The use of the tyrosine kinase inhibitor imatinib, which blocks the enzymatic action of the BCR–ABL fusion protein, has represented a critical advance in chronic myeloid leukemia (CML) treatment. However, a subset of patients initially fails to respond to this treatment. Use of...

  • BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry. Hamilton, A.; Elrick, L.; Myssina, S.; Copland, M.; Jørgensen, H.; Melo, J. V.; Holyoake, T.; Jørgensen, H // Leukemia (08876924);Jun2006, Vol. 20 Issue 6, p1035 

    In chronic myeloid leukaemia, CD34(+) stem/progenitor cells appear resistant to imatinib mesylate (IM) in vitro and in vivo. To investigate the underlying mechanism(s) of IM resistance, it is essential to quantify Bcr-Abl kinase status at the stem cell level. We developed a flow cytometry method...

  • Chronic Myelocytic Leukemia -- Part II: Approaches to and Molecular Monitoring of Therapy. Randolph, Tim R. // Clinical Laboratory Science;Winter2005, Vol. 18 Issue 1, p49 

    Focuses on a study which presented the approaches to and molecular monitoring of therapy for chronic myelocytic leukemia (CML). Evolution of the therapeutic approaches for the disease; Effectiveness of the Imatinib therapy as measured by molecular methods; Strategies for the management of CML...

  • Imatinib/nilotinib.  // Reactions Weekly;3/8/2008, Issue 1192, p21 

    The article describes the case of a 40-year old man and a 60-year old woman who experienced transient lymphoid bone marrow infiltration during treatment with imatinib and nilotinib, respectively, for chronic phase chronic myeloid leukemia. Both the patients achieved complete cytogenetic response...

  • ILLUSTRATIVE CASE SERIES: Newly Diagnosed CML. Hesdorffer, Charles // Clinical Oncology Alert;Nov2010, Vol. 26 Issue 11, p81 

    The article presents a case study of a 64-year-old man who was referred due to leukocytosis. He was previously diagnosed with pneumonia. He was thought to be suffering from chronic myelogenous leukemia (CML) and was prescribed with initial treatments pending the results of the diagnosis. The...

  • Comparison of long-term outcome of early versus late chronic phase imatinib receivers. Gürkan, Emel; Paydaş, Semra // Journal of Hematological Malignancies;Sep2012, Vol. 2 Issue 3, p8 

    The introduction of imatinib mesylate made a remarkable contribution to the management of patients with chronic myeloid leukemia. In this study, we assessed the long-term efficacy of imatinib exposure in patients with CML in chronic phase according to European recommendations which consists both...

  • Delivery of two normal twins exposed to imatinib and nilotinib during the first trimester of pregnancy in a woman with chronic myeloid leukemia. Mseddi, S. Hadiji; Kallel, F.; Amouri, H.; Affes, H.; Mdhaffar, M.; Elloumi, M. // Journal of Hematological Malignancies;Sep2012, Vol. 2 Issue 3, p74 

    We report here the case of a 35-year-old woman. She was diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia. Because of primary infertility, she received imatinib without contraception. Complete cytogenetic response was not obtained with 800 mg/day. As a result, the patient...

  • Nilotinib, dasatinib or imatinib in CML: no clear winner. Cooper, Nick // PharmacoEconomics & Outcomes News;6/23/2012, Issue 656, p7 

    Chronic myeloid leukaemia (CML) is characterised by three distinct phases: chronic phase (CP), accelerated phase (AP) and blast crisis (BC). CML is now largely treated with tyrosine kinase inhibitors (TKIs), such as the first- generation imatinib [Glivec] and the newer second-generation...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics